Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Other Accumulated Expenses (2021 - 2026)

Pliant Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $4.1 million for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 71.21% to $4.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Mar 2026, down 71.21% year-over-year, with the annual reading at $4.8 million for FY2025, 66.55% down from the prior year.
  • Other Accumulated Expenses was $4.1 million for Q1 2026 at Pliant Therapeutics, down from $4.8 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $23.0 million in Q3 2024 and troughed at $4.1 million in Q1 2026.
  • The 5-year median for Other Accumulated Expenses is $14.0 million (2023), against an average of $13.2 million.
  • Year-over-year, Other Accumulated Expenses skyrocketed 91.17% in 2022 and then plummeted 71.21% in 2026.
  • A 5-year view of Other Accumulated Expenses shows it stood at $11.2 million in 2022, then rose by 11.04% to $12.5 million in 2023, then rose by 15.31% to $14.4 million in 2024, then tumbled by 66.55% to $4.8 million in 2025, then fell by 13.8% to $4.1 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Other Accumulated Expenses are $4.1 million (Q1 2026), $4.8 million (Q4 2025), and $7.8 million (Q3 2025).